Imperial College London

DrLucaMagnani

Faculty of MedicineDepartment of Surgery & Cancer

Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2808l.magnani CV

 
 
//

Location

 

140ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Perone:2016:10.1530/JME-16-0062,
author = {Perone, Y and Magnani, L},
doi = {10.1530/JME-16-0062},
journal = {Journal of Molecular Endocrinology},
pages = {F1--F5},
title = {Going off the grid: ERα breast cancer beyond estradiol},
url = {http://dx.doi.org/10.1530/JME-16-0062},
volume = {57},
year = {2016}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Novel studies have linked cholesterol biosynthesis to drug resistance in luminal breast cancer. Structural data suggest that cholesterol metabolites, including 27-hydroxycholesterol (27-HC), can act as ERα ligands in these cells. Additionally, hypercholesterolemia has now been linked to breast cancer progression. The focus of this review is to briefly summarize these recent finding and discuss how epigenetic reprogramming is definitively connected to endogenous cholesterol biosynthesis. We elaborate on how these data support a working model in which cholesterol biosynthesis promotes autocrine, pro- invasive signaling via activation of a series of closely related transcription factors. Importantly, we discuss how this mechanism of resistance is specifically associated with aromatase inhibitors. Finally, we examine how the field is now considering the development of anti-cholesterol therapeutics and companion biomarkers to stratify and treat ERα breast cancer patients. In particular, we review recent progress in pharmaceutical strategies targeting the cholesterol molecular machinery in primary and secondary breast cancers.
AU - Perone,Y
AU - Magnani,L
DO - 10.1530/JME-16-0062
EP - 5
PY - 2016///
SN - 1479-6813
SP - 1
TI - Going off the grid: ERα breast cancer beyond estradiol
T2 - Journal of Molecular Endocrinology
UR - http://dx.doi.org/10.1530/JME-16-0062
UR - http://hdl.handle.net/10044/1/33104
VL - 57
ER -